cp wire

CP Wire Articles

  • The FDA is requiring additional information and analyses
  • No new cliincal studies are required

Sunovion Pharmaceuticals Inc. (Sunovion) announced on 1/31/19 that the... read more

Thu, 01/31/19 - 10:19 am

BioXyTran has filed for an offering of common stock that will bring in approximately $10 million. The company has two candidates that it intends to advance to pre-clinical development with the... read more

Thu, 01/31/19 - 10:05 am

Azitra, Inc., a company developing microbiome-based cosmetics and therapeutics to treat skin diseases and conditions, announced today that enrollment has been completed for the first human safety... read more

Wed, 01/30/19 - 10:18 am

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) reported on 1/30/19 that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("... read more

Wed, 01/30/19 - 10:00 am

Alector has filed for an IPO that will bring in approximately $180 million if options are exercised. The company is is focused on developing novel therapeutics that harness the brains immune... read more

Tue, 01/29/19 - 03:28 pm

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced on 1/28/19 that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa... read more

Tue, 01/29/19 - 01:24 pm

LXC Fund, based in Pittsburgh is seeking to raise $250 million according to this recent SEC... read more

Tue, 01/29/19 - 10:02 am
  • The agreement will lower out-of-pocket costs for patients
  • It will cover Brilinta prescriptions
  • Clinical outcomes will determine the level of shared costs between AstraZeneca... read more
Mon, 01/28/19 - 12:06 pm

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced on 1/26/19 that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United... read more

Mon, 01/28/19 - 10:10 am


This was a short work week for many due to MLK Day on Monday, but Tuesday started off Q4 earnings... read more
Sun, 01/27/19 - 07:07 pm
  • Coherus’ license period in the U.S. commences on December 15, 2023
  • Coherus will pay royalties to AbbVie
  • The company has six candidates in development

Coherus... read more

Fri, 01/25/19 - 10:41 am
  • ArQule is eligible to receive up to $326 million in regulatory and commercial milestone payments related to the BAL087 license agreement
  • BAL087 has U.S. and EU orphan drug... read more
Thu, 01/24/19 - 10:38 am

Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based... read more

Thu, 01/24/19 - 10:12 am
  • The research demonstrates that specific, human microbiome-derived bacteria assembled rationally into consortia can cooperatively enhance the responses to immune checkpoint inhibitors
  • ... read more
Thu, 01/24/19 - 12:19 am

Gossamer Bio announced terms for it's $230 Million IPO on 1/23/19. The company plans to offer 14.4 million shares at $16 per share. Insiders have expressed an interest in acquiring $100 million of... read more

Wed, 01/23/19 - 09:14 pm

Talee Bio, Inc. announced on 1/23/19 agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL... read more

Wed, 01/23/19 - 09:37 am

BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR... read more

Wed, 01/23/19 - 09:22 am

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has partnered and established a collaboration with the Ladak Laboratory at Western University,... read more

Tue, 01/22/19 - 10:53 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.